Is Cencora Inc. (COR) overvalued? · P/E 21, rev $321.33B
Cencora Inc. (COR) is a medical distribution company listed on NYSE.
This page asks whether Cencora Inc. (COR) looks expensive on cached numbers — not a short thesis.
Latest reported COR revenue for 2025-09-30 was $321.33B. Net income was $1.57B. Revenue was up 9.3% from 2024-09-30 to 2025-09-30. COR currently screens at market cap $53.91B and trailing P/E 21.2.
COR currently screens at market cap $53.91B and trailing P/E 21.2. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next COR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the COR stock page for the full model, not this heading.
Not investment advice.